DOI:
10.1055/s-00033990
TH Open
LinksClose Window
References
Peyvandi F, Scully M, Kremer Hovinga JA. , et al.
Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura.
J Thromb Haemost 2017;
15 (07) 1448-1452
We do not assume any responsibility for the contents of the web pages of other providers.